Journal article
Racial Differences in Presentation and Management of Follicular Non-Hodgkin Lymphoma in the United States: Report From the National LymphoCare Study
Cancer, Vol.118(19), pp.4842-4850
2012
DOI: 10.1002/cncr.27513
PMID: 22434428
Abstract
Background: Racial differences in follicular lymphoma (FL) in the United States have not been investigated.
Methods: The National LymphoCare Study is a multicenter, longitudinal, observational cohort study collecting data on treatment patterns and outcomes for patients with newly diagnosed FL in the United States between 2004 and 2007 without any predefined, study-specific intervention. The authors investigated differences between white (W) patients, African American (AA) patients, and Hispanic (H) patients.
Results: Among 2744 enrolled patients, there were 95 (3%) AA patients, 125 (5%) H patients, and 2476 (90%) W patients. Compared with W patients, more AA and H patients were diagnosed at age <45 years (P < .0001). H patients more commonly were diagnosed with grade 3 FL compared with AA and W patients (29%, 13%, and 18%, respectively; P = .019) and more commonly received rituximab plus chemotherapy as initial therapy compared with W patients (66% vs 50%; P = .036), while AA patients less commonly received anthracyclines (49% vs 64% in W patients; P = .027). H and AA patients who received rituximab plus chemotherapy were less likely than W patients to receive maintenance rituximab (27% vs 31% vs 40%, respectively; P = .031). At a median follow-up of 52 months, progression-free survival was similar between AA and W patients but was longer in H patients, and there was no difference in overall survival.
Conclusions: In the largest prospective cohort to date of AA and H patients with FL in the United States, AA and H patients were younger at presentation. Although racial differences in treatment patterns for FL were noted, additional follow-up is needed to determine the impact of these differences on survival.
Details
- Title: Subtitle
- Racial Differences in Presentation and Management of Follicular Non-Hodgkin Lymphoma in the United States: Report From the National LymphoCare Study
- Creators
- Chadi NABHAN - Oncology Specialists, S.C., Department of Medicine, Division of Hematology and Medical Oncology, Advocate Lutheran General Hospital, Park Ridge, Illinois, United StatesMichelle BYRTEK - Genentech, Inc, South San Francisco, California, United StatesMichael D TAYLOR - GenentechJonathan W FRIEDBERG - Department of Medicine, Division of Hematology and Medical Oncology, University of Rochester, Rochester, New York, United StatesJames R CERHAN - Department of Medicine, Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, Minnesota, United StatesJohn D HAINSWORTH - Department of Medicine, Division of Hematology and Medical Oncology, Sarah Cannon Research Institute, Nashville, Tennessee, United StatesThomas P MILLER - Department of Medicine, Division of Hematology and Medical Oncology, Arizona Cancer Center, Tucson, Arizona, United StatesJamie HIRATA - Genentech, Inc, South San Francisco, California, United StatesBrian K LINK - Department of Medicine, Division of Hematology and Medical Oncology, University of Iowa, Iowa City, Iowa, United StatesChristopher R FLOWERS - Department of Medicine, Division of Hematology and Medical Oncology, Emory University, Atlanta, Georgia
- Resource Type
- Journal article
- Publication Details
- Cancer, Vol.118(19), pp.4842-4850
- Publisher
- Wiley-Blackwell
- DOI
- 10.1002/cncr.27513
- PMID
- 22434428
- ISSN
- 0008-543X
- eISSN
- 1097-0142
- Language
- English
- Date published
- 2012
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
- Record Identifier
- 9984094312902771
Metrics
19 Record Views